Absence of venous thromboembolism risk following quadrivalent human papillomavirus vaccination, Vaccine Safety Datalink, 2008-2011.
Naleway, Allison L; Crane, Brad; Smith, Ning; Daley, Matthew F; Donahue, James; Gee, Julianne; Greene, Sharon K; Harrington, Theresa; Jackson, Lisa A; Klein, Nicola P; Tseng, Hung Fu; Vellozzi, Claudia; Weintraub, Eric S.
; 34(1): 167-71, 2016 Jan 02.
Artigo em Inglês | MEDLINE | ID: mdl-26549361
Evaluation of the risk of venous thromboembolism after quadrivalent human papillomavirus vaccination among US females.
Safety and Immunogenicity of the Quadrivalent HPV Vaccine in Japanese Boys: a Phase 3, Open-Label Study.
Immunogenicity and safety of quadrivalent human papillomavirus types 6/11/16/18 recombinant vaccine in chronic kidney disease stage IV, V and VD.
Quadrivalent HPV vaccine in HIV-1-infected early adolescent girls and boys in Kenya: Month 7 and 12 post vaccine immunogenicity and correlation with immune status.
The safety and immunogenicity of Quadrivalent HPV (qHPV) vaccine in systemic lupus erythematosus.
Reactogenicity of Cervarix and Gardasil human papillomavirus (HPV) vaccines in a randomized single blind trial in healthy UK adolescent females.
An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015.
Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa.
Unmasking in an observational vaccine safety study: Using type 2 diabetes mellitus as an example.
Safety of quadrivalent human papillomavirus vaccine (Gardasil) in pregnancy: adverse events among non-manufacturer reports in the Vaccine Adverse Event Reporting System, 2006-2013.